Previous 10 | Next 10 |
home / stock / azncf / azncf news
Adagene has filed to raise $132 million in a U.S. IPO. The firm is advancing antibody-based treatment candidates for various cancers. ADAG has a capable CEO but the firm is still ultra early stage and the IPO is priced well above the typical range for life science firms. I'll ...
Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. BOLT has produced early efficacy results for its lead program and has an impressive investor syndicate, so the IPO is worth consideration...
The moment of truth arrived. NVAX reported 89% efficacy for its COVID-19 vaccine. The stock shot up over 60% on the news. I expect Emergency Use Authorization soon. NVAX's supply chain could allow it to take market share from competitors. NVAX trades at 3.7x expected 2021 COVID-19...
Risk and disruption ruled in 2020 as we experienced the first modern day pandemic. We changed the way we live and the way we work. Portfolio performance was greatly affected by pandemic preparedness. In 2020, only a handful of sectors performed well. One needed to be in tech, cons...
The public tete-a-tete between AZN and the EU could result in the EU restricting supply of AZN's COVID-19 vaccine outside the EU. The vaccination rollout has been slow in the U.S. as well. PFE or MRNA could capitalize on any AZN supply constraints. If the efficacy of AZN's vaccine...
Some cash is king, Covid-19 plays, Green renewable energy & EVs led by Biden, Digital payments & fintech innovation will be new habits, Buy quality SPACs as early as possible. Other 2021 investment trends include Space tourism (and point to point travel), Cybersecurity, Artifi...
The company's vaccine is being rolled out at scale. It has a fairly low price and a lot of the stock may be profit-free. There will be a sizeable revenue bump, but the profit benefit will be smaller and short-lived on my assessment. The vaccine doesn't change the fundamentals ...
Veeva is building the Industry Cloud for the global life sciences industry with solutions including a CRM suite, content and data management, and AI-powered data analytics. In Q3, Veeva reported a revenue growth rate of 34% y/y (acceleration) and a healthy gross margin of 72% (q/q imp...
IQVIA demonstrates a strong sequential growth pattern, in near recovery to pre-pandemic volumes. Management have reinstated the buyback program, with ~$1 billion in authorization, and look set on acquisition targeting across FY2021. We feel shares are worth ~$197 at this point, an...
Moderna's vaccine delay is hardly fault of its own. The bigger investment picture becomes visible when you ignore the small setbacks and concentrate on the larger factors - in this case, mRNA-1273's superior ease of storage and strong efficacy. Additions to the company's vaccine p...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...